JPRN-UMIN000052904招募中未知
A controlled, randomized, parallel-group, prospective study of lumbar-abdominal shunting for normal pressure hydrocephalus complicated by Parkinson's disease and related disorders. - Shunt-PD study
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 60years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Select patients with no pre-existing subarachnoid hemorrhage, meningitis, head trauma, congenital hydrocephalus, or aqueductal stenosis.If the CSF test shows CSF amyloid-beta42 < 500 pg/ml, CSF total tau > 600 pg/ml, and CSF phosphorylated tau > 60 pg/ml, the patient is likely to have Alzheimer's disease and should be excluded.
研究者
相似试验
进行中（未招募）
不适用
A randomized, open, controlled parallel group, multi-center study to evaluate the efficacy and safety of Norspan versus Tiparol Retard in subjects with chronic, moderate to severe osteoarthritis pain of the hip and/or knee.Pain due to osteoarthritis of the hip and/or kneeMedDRA version: 8.1Level: LLTClassification code 10031161Term: OsteoarthritisEUCTR2006-003233-32-SEMundipharma AB
终止
不适用
A randomized controlled trial of daily aerobic exercise for inpatient cannabis withdrawalACTRN12615000211561niversity of Sydney80
进行中（未招募）
不适用
An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.HyperphosphataemiaMedDRA version: 9.1Level: LLTClassification code 10020711Term: HyperphosphataemiaEUCTR2008-004730-25-BEINEOS Healthcare Limited780
进行中（未招募）
不适用
An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia - ACT 402EUCTR2008-004730-25-ITINEOS HEALTHCARE LIMITED780
进行中（未招募）
不适用
An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.EUCTR2008-004730-25-EEINEOS Healthcare Limited780